---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-018210"
form_type: "8-K"
ticker: "LNSR"
cik: "0001320350"
company_name: "LENSAR, Inc."
filed_at: "2022-09-08T23:59:59+00:00"
generated_at: "2026-06-23T12:38:44.762051+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# LENSAR applies for CE Mark certification of ALLY System in European Union

## Summary
- Application for CE Mark certification of the ALLY Adaptive Cataract Treatment System submitted.
- CE Mark would allow commercialization of ALLY in the European Union following successful certification.
- Application follows U.S. FDA clearance of ALLY in June 2022 and the U.S. commercial launch.
- Company plans to use distributor network for EU commercialization, similar to first-generation system.

## SEC filing metadata
- accession: 0000950170-22-018210
- form_type: 8-K
- ticker: LNSR
- cik: 0001320350
- company_name: LENSAR, Inc.
- filed_at: 2022-09-08T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1320350/000095017022018210/0000950170-22-018210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1320350/000095017022018210/lnsr-20220908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-018210
- JSON: https://secwatch.observer/filing/0000950170-22-018210.json
- Plain text: https://secwatch.observer/filing/0000950170-22-018210.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.